Welcome to our dedicated page for Inspire Medical SEC filings (Ticker: INSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evaluating a company built around an implantable sleep-apnea device means combing through pages of clinical data, FDA correspondence, and reimbursement notes. Inspire Medical Systems� filings can feel like a medical journal, yet missing a single update on trial results or executive trades can sway your view of INSP’s value.
Stock Titan’s AI bridges that gap. Our platform ingests every document the moment it hits EDGAR, from a routine Inspire Medical Systems quarterly earnings report 10-Q filing to the surprise Inspire Medical Systems 8-K material events explained. Instant, plain-English summaries highlight growth in implant procedures, new CMS coverage decisions, and supply-chain disclosures—turning technical paragraphs into clear takeaways.
Use cases investors ask for every quarter are built in:
- Follow Inspire Medical Systems insider trading Form 4 transactions and receive alerts on Inspire Medical Systems Form 4 insider transactions real-time before the market closes.
- Dive into an Inspire Medical Systems annual report 10-K simplified to see unit economics on each neurostimulator sold.
- Compare R&D spending with revenue in our Inspire Medical Systems earnings report filing analysis.
Need context fast? Ask in plain language—“understanding Inspire Medical Systems SEC documents with AI� or “Inspire Medical Systems proxy statement executive compensation”—and the system surfaces the exact table or chart. Whether you’re tracking Inspire Medical Systems executive stock transactions Form 4 or verifying how many centers are implanting the device, you’ll find every disclosure, timestamped and explained simply.
Inspire Medical Systems (INSP) announced that Chief Financial Officer Richard J. Buchholz has notified the company he will step down to pursue other professional opportunities. Mr. Buchholz and the company entered a Transition and Separation Agreement under which his resignation will be effective on the earlier of December 31, 2025 or the date a permanent successor CFO commences employment. He will remain principal financial and accounting officer through that date and then serve as a financial advisor through February 28, 2026 while receiving base salary and benefits.
The agreement provides for a cash payment equal to nine months of his 2025 annual base salary and up to nine months of COBRA coverage. The company has engaged a leading executive search firm to recruit a new CFO. The filing discloses customary confidentiality, non-disparagement and release provisions and incorporates the full separation agreement as Exhibit 10.1 and a press release as Exhibit 99.1.
Inspire Medical Systems CFO Richard Buchholz reported multiple acquisitions of company stock on 08/19/2025. He exercised employee stock options and purchased shares, increasing his direct holdings. The Form 4 shows exercises of options with strike prices of $71 (17,849 shares) and $42.15 (7,159 shares), plus recognition of shares withheld for tax obligations (2,649; 2,455; 276) and 113 shares from the 2018 Employee Stock Purchase Plan. After the transactions, his reported direct common stock holdings range across entries (for example, 61,247 and 58,598 shares). Certain family members are reported as indirect holders (each 1,475 shares).
Inspire Medical Systems disclosed that its Board has authorized the repurchase of up to $200.0 million of the company’s outstanding common stock. The filing indicates the board approved a buyback authorization but does not include details on timing, methods, or the pace of repurchases.
The filing also furnishes the company press release as Exhibit 99.1 and includes Inline XBRL cover page tags. No financial results, program specifics, or additional transaction terms are provided within this report.
FAQ
What is the current stock price of Inspire Medical (INSP)?
What is the market cap of Inspire Medical (INSP)?
